The novel influenza A (H1N1) 2009 virus has emerged to cause the first pandemic of the twenty-first century. Disease outbreaks caused by the influenza A (H1N1) virus have prompted concerns about the potential for a pandemic and have driven the development of vaccines against this subtype of influenza A. In this study, we developed a monovalent influenza A (H1N1) split vaccine and evaluated its effects in BALB/c mice. Mice were immunized subcutaneously with 2 doses of the vaccine containing hemagglutinin (HA) alone or HA plus an aluminum hydroxide (Al(OH) 3 ) adjuvant. Immunization with varying doses of HA (3.75, 7.5, 15, 30, 45 or 60 mg) was performed to induce the production of neutralizing antibodies. The vaccine elicited strong hemagglutination inhibition (HI) and microneutralization, and addition of the adjuvant augmented the antibody response. A preliminary safety evaluation showed that the vaccine was not toxic at large doses (0.5 ml containing 60 mg HA1600 mg Al(OH) 3 or 60 mg HA). Moreover, the vaccine was found to be safe at a dose of 120 mg HA11200 mg Al(OH) 3 or 120 mg HA in 1.0 ml in rats. In conclusion, the present study provides support for the clinical evaluation of influenza A (H1N1) vaccination as a public health intervention to mitigate a possible pandemic. Additionally, our findings support the further evaluation of the vaccine used in this study in primates or humans.
INTRODUCTION
A swine-derived influenza A (H1N1) virus is currently responsible for an outbreak of infections among humans, with laboratory-confirmed cases reported in several countries and clear evidence of human-tohuman transmission.
1, 2 The virus is a new H1 subtype of hemagglutinin (HA), against which there is presently little immunity in humans. As reported by the World Health Organization on 1 July 2009, 26 laboratory-confirmed cases have been detected worldwide, including seven fatal cases (http://www.who.int/csr/don). Meanwhile, the World Health Organization raised the influenza pandemic alert level from phase 5 to phase 6 on 11 June 2009, and recommended that all countries enhance their global surveillance of and diagnostic capacity for influenza A (H1N1) infections. The current outbreak of influenza A (H1N1) underscores the necessity for all nations to have effective pandemic preparedness plans and coordinated responses. It also highlights the need for close epidemic surveillance and the control of influenza infections in pigs and poultry. Therefore, the development of an effective vaccine against influenza A (H1N1) is a matter of considerable urgency.
Influenza vaccines will be a pivotal prophylactic intervention to mitigate the consequences of pandemic influenza by reducing morbidity and mortality. 3, 4 Importantly, in an influenza pandemic, most people will be immunologically naive to the novel subtype, and 2 vaccine doses will probably be required to induce an acceptable antibody response. Adjuvants are therefore required to elicit protective immune responses at antigen doses equal to or lower than those used in current seasonal influenza vaccines. [5] [6] [7] Aluminum salts are the most widely used adjuvants in licensed vaccines with an excellent safety profile.
In the present study, we developed a human candidate monovalent influenza A (H1N1) split vaccine and evaluated its immune effects in BALB/c mice. The vaccine strain used in this study was prepared by reverse genetics based on an influenza virus that caused an outbreak in the United States. Our results show that the vaccine induced significant serum hemagglutination inhibition (HI) and neutralization. Furthermore, the vaccine was well tolerated and caused a strong antibody response when formulated with an adjuvant (Al(OH) 3 ). These findings provide experimental support for evaluating the efficacy of influenza A (H1N1) vaccines in primates or humans. dark cycles. The serum levels of immunoglobulin G (IgG), IgA and IgM as well as HI were determined in groups consisting of six mice each.
Preparation of the vaccine
The 2009 H1N1 vaccine virus (New York Medical College (NYMC) X-179A) was generated from the influenza A/California/07/ 2009(H1N1) strain by means of classical reassortant methods. The gene segments encoding HA, neuraminidase and the polymerase PB1 were derived from the influenza A/California/07/2009(H1N1) strain, with the remaining genes taken from influenza A/PR8/8/34 as a backbone. 8 The strain was supplied by the National Institute for Biological Standards and Control (NIBSC, UK) and was a pandemic vaccine strain recommended for use in vaccine development. The vaccine was formulated and produced by Hualan Vaccine Inc. (Xinxiang, Henan, China) as an influenza A (H1N1) split vaccine with or without Al(OH) 3 as an adjuvant, and was supplied in 0.5-ml prefilled single-dose syringes. The NYMC X-179A vaccine was propagated in the allantoic cavity of 10-day-old specific pathogen-free embryonated chicken eggs at 35 uC. Allantoic fluids were harvested 48 h after inoculation. Virus titers were determined using HA assays. The vaccine was generated according to standard techniques. Briefly, the seed virus was grown to a high titer in eggs, and then the virions were purified by means of centrifugation, inactivated with formalin, disrupted with Triton X-100, and filtered to remove bacteria. An inactivated split influenza A (H1N1) vaccine was produced on a pilot scale using Good Manufacturing Practices. The vaccine contained all of the proteins found in the viral particle, with the major component being HA (about 30% of the total protein). The vaccine was subsequently calibrated to 84 mg/ml HA. The adjuvant Al(OH) 3 was supplied in prefilled syringes containing 600 mg of aluminum. The vaccine was stored at 4 uC until use.
Immunization and sample collection
The animals were kept under specific pathogen-free conditions and immunized subcutaneously twice at a 14-day interval. On days 0 and 14, the mice received the influenza A (H1N1) split vaccine containing 3.75, 7.5, 15, 30, 45 or 60 mg of HA with or without 1.2 mg/ml Al(OH) 3 in a total volume of 0.2 ml in phosphate-buffered saline (PBS, pH 7.4). Each group consisted of six mice. The animals were killed on day 28, and their blood was collected. The samples were stored at 220 uC until use.
HI assay
Serum neutralization activity was measured by HI assays 9 using sera collected at 2 weeks after the first or second injection. Briefly, receptordestroying enzyme-treated serum samples were serially diluted (twofold) in V-bottom 96-well plates. Approximately 4 HA units of viral antigen were incubated with the serum for 30 min at room temperature, followed by the addition of 0.5% turkey erythrocytes and incubation at room temperature for 40 min. The inhibition of HA at the highest serum dilution was defined as the HI titer for the sample. All experiments were performed three times.
Microneutralization assay
Serum neutralization antibody titers were determined by microneutralization assays as described. 10 Briefly, Madin-Darby canine kidney (MDCK) cells were seeded at 1310 6 cells/well in 96-well plates and cultured at 37 uC to form a monolayer. Serial twofold dilutions of heatinactivated (56 uC for 45 min) sera were then mixed separately with 100 TCID 50 of the H1N1 strain and incubated at room temperature for 1 h. Next, the mixture was added to a monolayer of MDCK cells in triplicate. The neutralizing titers of mouse antisera that completely prevented cytopathic effect at reciprocal dilutions were calculated. Sera from mice that received PBS alone were used as negative controls.
Measurement of antigen-specific antibody levels
The serum levels of IgG, IgA and IgM antibodies against influenza A (H1N1) antigen were determined separately by indirect enzymelinked immunosorbent assays. Briefly, U-bottomed 96-well ELISA plates were coated with 400 ng of purified influenza A (H1N1) vaccine antigen in 100 ml of coating buffer (0.1 M carbonate/bicarbonate, pH 9.6) and incubated overnight at 4 uC. The antigen-coated plates were then washed with PBS containing 0.05% Tween 20 (PBS-T), and non-specific sites were blocked with 100 ml of blocking buffer (PBS containing 5% skim milk) for 1 h at 37 uC. One hundred microliters of serum and mucosal wash fluid diluted 1:100 and 1:50, respectively, in PBS-T, were added in triplicate and incubated for 1 h at 37 uC. After washing three times with PBS-T, 100 ml (1:1000 diluted in PBS) of horseradish peroxidase-conjugated goat antimouse IgG, IgA and IgM (Sigma, St Louis, MO, USA) were added and the plate was incubated at 37 uC for 1 h. After washing three times with PBS-T, 100 ml of 3,3',5,5'-tetramethylbenzidine (Sigma) was added and the solution was allowed to stand for a suitable amount of time. The reaction was stopped with 25 ml of 2 M H 2 SO 4 , and the absorbance at 450 nm was measured using an ELISA plate reader.
The antibody-secreting cell (ASC) response
The number of ASCs was evaluated by an enzyme-linked immunospot (ELISPOT) assay with the following modification. ELISPOT plates were coated overnight at 4 uC with 5 mg/ml split virus vaccine. Lymphocytes (5310 5 cells) were added in duplicate and incubated overnight. The antibodies (IgG, IgA and IgM) secreted by the lymphocytes were detected by incubation with biotin-labeled goat antimouse class-specific antibodies for 2 h at room temperature. Following development, the number of spots was counted using an ImmunoSpot series 3 automatic ELISPOT reader.
Cytokine assays
Antibodies against the mouse cytokines used in our cytokine ELISPOT assays were purchased from BD/Pharmingen (San Diego, CA, USA). Antimouse interferon-c (INF-c) and IL-4 antibodies (5 mg/ml in coating buffer) were used to coat multiscreen 96-well filtration plates (Millipore, Bedford, MA, USA). Freshly isolated splenocytes (1.0310 6 cells) were then added to each well and stimulated with influenza A (H1N1) split virus antigen at 5 mg/ml. Next, the plates were incubated for 40-44 h at 37 uC under 5% CO 2 . Development and counting of the cytokine ELISPOTs were performed using an ImmunoSPOT series 3 automatic ELISPOT reader.
Evaluation of the safety of the vaccine in mice Fifty male and 50 female ICR mice (19-21 g each) were used. The mice were inoculated with a high dose (0.5 ml containing 60 mg HA1600 mg Al(OH) 3 or 60 mg HA) or a low dose (0.25 ml containing 30 mg HA1300 mg Al(OH) 3 or 30 mg HA) of the vaccine. The solvent control group was injected with 2 mg/kg Al(OH) 3 , while the negative control group was injected with PBS. The dosages were prepared by isochoric suspension for use in subcutaneous injections. The effect of vaccination on the nervous system was surveyed.
Dose-safety evaluation in rats
Sprague-Dawley rats were vaccinated subcutaneously five times at an interval of 10 days. Three of the five groups were vaccinated with a high dose (1.0 ml containing 120 mg HA11200 mg Al(OH) 3 or 120 mg HA) or a low dose (0.5 ml containing 60 mg HA1600 mg Al(OH) 3 or 60 mg HA). Two of the five groups were injected with Al(OH) 3 and PBS (control). Toxicity of the vaccine was monitored.
Statistical analysis
All data are expressed as mean6SD unless otherwise stated. Analysis of variance was used to compare the treatment group means for a given time point and to compare mean responses between time points. All tests were performed using SPSS 17.0 software. The analysis of variance F-statistics were used to assess significance at the 5% level. The values plotted represent the antibody titers for each group; error bars indicate 95% confidence upper limits.
RESULTS
Comparison of the efficacy of the vaccine by HI assay using sera from the immunized mice No influenza A (H1N1)-specific antibody was detected before vaccination. The HI and neutralization antibody titers of individual mice were measured on days 14, 21 and 28 after administration of the first dose of vaccine. Following the administration of the second dose, the time point for detectable HI increased up to day 14 in all antigentreated mouse groups with or without adjuvant (Figure 1 ). Greater HI titers were detected in the adjuvanted groups than in the non-adjuvanted groups following immunization at the same dosage. In particular, the mice in two vaccine groups (7.5 mg adjuvanted and 15 mg non-adjuvanted) had relatively more HI antibodies at the lowest dose of antigen. These results show that immunization with 2 doses was superior to that with 1 dose for individuals without pre-existing immunity. Moreover, as shown in Figure 2 , influenza A (H1N1) with the adjuvant (Figure 2a ) induced a significant increase in HI compared to the non-adjuvanted groups (Figure 2b ), especially at 2 weeks after immunization. 
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Determination of the virus-neutralizing titers
Low antibody titers were detected by microneutralization assays on day 14 after the first vaccination. Serum neutralization antibodies were detectable in each group on day 14 after the second vaccination in all animals. Of note, Al(OH) 3 had an obvious adjuvant effect on day 14 (Figure 3a) or day 28 after the first dose (Figure 3b) . Generally, little to no neutralization was detected after the first vaccination, and the highest micronuclei titers were observed in the mice vaccinated with the adjuvanted vaccine (60 mg). However, there were no significant differences among 7.5, 15 and 30 mg of vaccine antigen in the adjuvanted groups. Mice vaccinated with PBS had no detectable serum HI antibodies (,10) against the virus.
Kinetics of the serum antibody response
Influenza-specific serum IgG, IgA and IgM responses were measured in the mice on days 14, 21 and 28 following the first immunization.
As shown in Figure 4 , IgG was present at higher titers at each time point after immunization. Following vaccination, the IgG titers increased until their peak on day 28. After the second vaccination in the 60-mg adjuvanted groups, a significant increase in IgG (1:51 200) was observed on day 14 with no boost in the serum IgM or IgA level (data not shown). The same tendency was noted in the adjuvanted and non-adjuvanted groups, which might be related to the route of administration since subcutaneous immunization cannot induce effective mucosal immunity. Mice vaccinated with PBS or Al(OH) 3 alone had no detectable serum anti-influenza IgG antibody titer (,10).
ASC response
No influenza-specific ASCs were detected prior to vaccination. The influenza A (H1N1)-specific ASC response was dominated by IgG antibody classes after one and 2 doses of the vaccine, whereas low numbers of IgA ASCs were found (data not shown). The greatest numbers of ASCs were observed on day 28 following immunization. The greatest numbers of IgG influenza-specific ASCs (ranging from 10 to 90 per 500 000 lymphocytes) were detected on day 28 after the first immunization in the splenic lymphocytes of the BALB/c mice ( Figure 5 ). As for the serum IgA response, only small amounts of IgA were detected after vaccination (data not shown). 
Determination of specific INF-c and IL-4
To determine whether the vaccine could also induce cell immune responses, we measured the production of INF-c and IL-4 using ELISPOT in mouse splenic lymphocytes at 2 weeks following the final immunization. Splenic lymphocytes stimulated in vitro with the split influenza A (H1N1) virus vaccine had increased cytokine levels. The high-dose group secreted significantly more INF-c compared to the low-dose group (Figure 6a ). The same tendency was noted in the adjuvanted and non-adjuvanted groups, whereas IL-4 production was identical to that of INF-c in most groups (Figure 6b ). Overall, these data demonstrate that the influenza A (H1N1) split vaccine induced stronger systemic Th1-and Th2-type cytokine responses in the spleen. Moreover, most of the groups that received the adjuvant exhibited significantly greater Th2-type (IL-4) cytokine responses systemically in the spleen.
Evaluation of the safety of the vaccine in mice
No significant effects on the nervous system of the mice was observed after the subcutaneous injection of 0.5 ml of the influenza vaccine (60 mg HA1600 mg Al(OH) 3 or 60 mg HA) as indicated by assays of general behavior, locomotor activity, subthreshold hypnotic dosage, sodium pentobarbital cooperation and rotating coordination.
Dose-safety evaluation of the vaccine in rats
Sprague-Dawley rats were vaccinated five times by subcutaneous injection. Granuloma nodules observed at the injection site were gradually diminished after discontinuation of the inoculations. There was no obvious change in the blood parameters, organ weight, liver index, spleen weight or other parameters, suggesting that no toxic reactions were induced at a dose of 120 mg HA11200 mg Al(OH) 3 or 60 mg HA in 1.0 ml.
DISCUSSION
At present, the emergence of new influenza A (H1N1) virus subtypes with human-to-human transmissibility is of great public health concern, and the global increase in the number of influenza A (H1N1) outbreaks has heightened the need for pandemic preparedness against this subtype. A safe and effective vaccine is urgently needed. [11] [12] [13] [14] So far, the development of an effective vaccine is the best means of protection for humans against the emergence of an influenza A (H1N1) virus with high transmissibility between humans. [15] [16] [17] Although it could take many years for a successful vaccine to transit from bench to bedside, sequencing of the viral genome has greatly facilitated the design of a variety of vaccines. If an immunogenic vaccine could be rapidly produced and deployed, it would be of great help in reducing morbidity and mortality due to pandemic influenza. 18 Reverse genetics may be used to save a considerable amount of time in the production of a pandemic vaccine. In this study, we prepared a monovalent influenza A (H1N1) split vaccine and evaluated its effects in BALB/c mice. The split vaccine was prepared from a genetically reassortant vaccine virus (NYMC X-179A) that was produced by Figure 5 Examination of the IgG antibody response after vaccination by ELISPOT assay. Mice were immunized subcutaneously twice at a 2-week interval with HA from the influenza A (H1N1) vaccine. On day 14 after the final immunization, pools of three mice per group were killed and single-cell suspensions were prepared from the spleens for ELISPOT assay. The number of ASCs is shown per 500 000 lymphocytes. The bars show the mean number of specific ASCs per 500 000 lymphocytes6SD. The data are mean6SD from two experiments. ASC, antibodysecreting cell; ELISPOT, enzyme-linked immunospot; HA, hemagglutinin; IgG, immunoglobulin G. Response of BALB/c mice to H1N1 vaccine PH Yang et al 120 reverse genetics. Since aluminum is the only adjuvant approved for clinical applications, the influenza A (H1N1) split vaccine was adjuvanted with a commonly used non-proprietary adjuvant, Al(OH) 3 , which was formulated extemporaneously immediately prior to administration. Our report provides solid experimental data for preclinical studies of the prevention and treatment of influenza A (H1N1).
The current influenza vaccine manufacturing capacity is insufficient to meet the global demand for a pandemic vaccine, particularly if 2 doses of vaccine are required to elicit an adequate antibody response. 19 Whole-virus vaccines have proven to be more immunogenic when compared directly to split or subunit vaccines. However, most vaccine manufacturers have seen the benefits of split vaccine production due to smaller antigen doses and reduced side effects. Current seasonal influenza vaccines contain 15 mg of HA from each of the three seasonal strains. In contrast, very high antigen doses (up to 90 mg of HA) are required for non-adjuvanted avian influenza split viruses to elicit a sufficient antibody response to meet Committee for Medical Products for Human Use licensing criteria. 3, 20, 21 Furthermore, the results of the present study underscore the need for effective adjuvants to enhance the immune response to split or subunit pandemic influenza vaccines. Aluminium-salt adjuvants are readily available and inexpensive, and have been shown to augment the antibody response after 2 doses of candidate pandemic influenza vaccine, either of split or whole-virus formulations. 22 Therefore, we selected an aluminum-salt adjuvant for our vaccine. The results of this study confirm and extend previous data showing that adjuvants are necessary to enhance the immune response. In addition, our results prove that more effective adjuvants than aluminum salts are needed to induce a satisfactory immune response at an acceptable antigen dose. Hitherto, the most promising adjuvants have been oil-in-water emulsion systems such as MF59 and AS, which greatly enhanced homologous and crossreactive antibody responses after H5 vaccination even at low antigen concentrations (3.8-7.5 mg of HA) in humans. 3, 23, 24 Several species of laboratory animals have proven to be useful in research on influenza. Ferrets are considered the best available model for influenza research, and sera from ferrets post-infection are the World Health Organization's standard for the antigenic analysis of human influenza viruses. One tremendous advantage of ferrets is that influenza viruses can replicate in the respiratory tract of ferrets, resulting in acute respiratory illness that is characterized by such clinical signs as fever, rhinorrhea, and sneezing; moreover, ferrets have a similar disease complexity to that of humans. However, many host factors found associated with humans are missing from or have not yet been discovered in ferrets. The costs of ferrets, including the space needed for housing and the availability of animals without prior exposure to influenza (influenza virus seronegative), are still an issue. 25, 26 Although rhesus macaques are not currently susceptible to influenza viruses, the costs of housing and identification of immune reagents that may make this species more susceptible to influenza remain to be determined. For these reasons, the use of rhesus macaques in influenza studies is limited and inappropriate. 26, 27 In contrast, mice, particularly BALB/c mice, are currently intensively employed in studies of disease pathogenesis and vaccine efficacy. Influenza viruses rarely cause such symptoms as respiratory tract disease in mice, and these viruses must be adapted to replicate to high titers in mice. Mice also do not exhibit some of the clinical symptoms detected in humans. However, many clinical signs of influenza that seem to be markers of disease severity can be measured in mice. In addition, the ready availability of mice, their relatively low cost, the variety of genetic backgrounds and targeted defects available, and the immunologic reagents available to render mice susceptible to influenza, make this species an attractive and heavily utilized animal model for studies of influenza. Thus, it is important to assess the immune response to influenza A (H1N1) vaccines in different animal models to establish appropriate models for the preclinical evaluation of vaccines. 28, 29 The efficacy and protective effect of the influenza A (H1N1) split vaccine were not investigated in this study; thus, additional studies will be needed to determine the efficacy, immunogenicity, safety, toxicity and other pharmacological parameters of the influenza A (H1N1) vaccine using appropriate experimental animals before their protective effects in primates and humans can be tested.
Cytotoxic T-cell responses persist and protect against influenza infection in animal models. 30 Of note, we measured CD4 1 T-cell responses in the present study, and our results show that different doses of the influenza A (H1N1) split vaccine induced not only systemic antibody responses, but also Th1 (INF-c) and Th2 (IL-4) responses. As for influenza-vaccine production, a high virus yield is a critical factor because it can reduce cost and sustain longer immune protection periods by providing sufficient antigens. 31, 32 Importantly, the influenza (H1N1) split vaccine produced a satisfactory effect against influenza-virus infection at the lowest antigen dose tested (the vaccine at a dose of 7.5 mg with Al(OH) 3 and 15 mg of antigen alone were the optimal conditions). The promising results produced in this study concerning the safety and immunogenicity of the influenza H1N1 split vaccine support their careful evaluation in phase-1 clinical trials in humans.
Influenza pandemic preparedness has focused mostly on influenzavirus subtypes H5 and H7. [33] [34] [35] Nevertheless, it is impossible to predict the influenza subtype that will cause a pandemic. Thus, it is important to prepare influenza-virus vaccines against different subtypes and carefully evaluate their safety and immunogenicity in clinical studies prior to a pandemic. Taken together, the preclinical evaluation of the influenza A (H1N1) split vaccine described in this study indicates that NYMC X-179A is a promising vaccine candidate and that further clinical evaluation of the vaccine is justified.
